Human TNF can induce nonspecific inflammatory and human immune-mediated microvascular injury of pig skin xenografts in immunodeficient mouse hosts.
TNF activates endothelial cells to express cell surface molecules that are necessary to recruit a local infiltrate of leukocytes. Because the actions of this proinflammatory cytokine are not species restricted, we investigated whether human TNF can up-regulate porcine endothelial adhesion molecules to elicit human T cell infiltration and damage of pig skin xenografts in a chimeric immunodeficient mouse model. We have previously demonstrated the vigorous rejection of human skin allografts and the absence of injury to porcine skin xenografts in human PBMC-SCID/beige mice. Intradermal administration of human TNF at high doses (600 or 2000 ng) caused nonspecific inflammatory damage of pig skin grafts, whereas low concentrations of TNF (60 or 200 ng) resulted in human PBMC-dependent injury of porcine endothelial cells. There was a strong correlation among pig skin xenograft damage, human T cell infiltration, and the TNF-induced up-regulation of swine MHC class I and class II molecules, VCAM-1, and, in particular, the de novo expression of porcine E-selectin. The microvascular damage and leukocytic infiltration elicited by TNF were enhanced by porcine IFN-gamma, suggesting that xenografts may be less prone to cytokine-mediated injury due to the species-restricted effects of recipient IFN-gamma. Our results indicate that maintenance of a quiescent endothelium, which does not express E-selectin or other activation-dependent adhesion molecules, is important in preventing human anti-porcine T cell xenoresponses in vivo and that TNF signaling molecules and TNF-responsive gene products are appropriate therapeutic targets to protect against human T cell-mediated rejection of pig xenografts.
Kirkiles-Smith
N C
NC
Interdepartmental Program in Vascular Biology and Transplantation, Boyer Center for Molecular Medicine, Yale University School of Medicine, New Haven, CT 06510, USA.
Tereb
D A
DA
Kim
R W
RW
McNiff
J M
JM
Schechner
J S
JS
Lorber
M I
MI
Pober
J S
JS
Tellides
G
G
D019264:Adoptive Transfer; D000328:Adult; D000818:Animals; D015815:Cell Adhesion Molecules / Q000096:biosynthesis; D004306:Dose-Response Relationship, Immunologic; D004357:Drug Synergism; D004730:Endothelium, Vascular / Q000276:immunology / Q000378:metabolism / Q000473:pathology; D006084:Graft Rejection / Q000235:genetics / Q000276:immunology / Q000473:pathology / Q000503:physiopathology; D006649:Histocompatibility Antigens / Q000096:biosynthesis; D006801:Humans; D007371:Interferon-gamma / Q000633:toxicity; D051379:Mice; D008810:Mice, Inbred C57BL; D016513:Mice, SCID; D008833:Microcirculation / Q000276:immunology / Q000473:pathology; D016511:Severe Combined Immunodeficiency / Q000235:genetics / Q000276:immunology* / Q000473:pathology* / Q000503:physiopathology; D016038:Skin Transplantation / Q000009:adverse effects / Q000276:immunology* / Q000473:pathology*; D013552:Swine; D013601:T-Lymphocytes / Q000637:transplantation; D014183:Transplantation, Heterologous / Q000009:adverse effects; D014409:Tumor Necrosis Factor-alpha / Q000633:toxicity*; D015854:Up-Regulation / Q000276:immunology
D015815:Cell Adhesion Molecules; D006649:Histocompatibility Antigens; D014409:Tumor Necrosis Factor-alpha; D007371:Interferon-gamma